The US Department of Justice noted that total recoveries pertaining to allegations of generic price fixing have exceeded $500m, after Teva became the seventh company to settle civil claims for its alleged involvement in a pricing conspiracy for three drugs, including pravastatin.
The Israeli firm has agreed to pay $25m to settle allegations that it violated sections of the Anti-Kickback Statue by conspiring with other manufacturers to fix prices and/or allocate markets for the widely-used statin,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?